Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype

Abstract DNA-hypomethylating agents (HMAs) induce notable remission rates in AML/MDS patients with TP53 mutations; however, secondary resistance often develops rapidly. In the DECIDER trial (NCT00867672), elderly AML patients (also those with adverse genetics) randomized to all-trans retinoic acid (...

Cijeli opis

Bibliografski detalji

Glavni autori:	Johanna Thomas, Usama-Ur Rehman, Helena Bresser, Olga Grishina, Dietmar Pfeifer, Etienne Sollier, Konstanze Döhner, Christoph Plass, Heiko Becker, Claudia Schmoor, Maike de Wit, Michael Lübbert
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2024-09-01
Serija:	Clinical Epigenetics
Online pristup:	https://doi.org/10.1186/s13148-024-01737-4
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!